Amsterdam, July 6 2007 -- Aescap Venture invests € 4 million in the Dutch biotech company to-BBB. to-BBB’s proprietary technology brings drugs to the brain that normally can not enter the brain due to the neuroprotective blood-brain barrier.
The company’s lead product is fighting lethal viral infections of the brain using an existing broad-spectrum antiviral drug. The company’s technology also targets neurodegenerative disorders like Alzheimer’s disease, Stroke, Lysosomal Storage diseases and brain tumors.
Dr. Pieter Gaillard, CEO of to-BBB: “I am very pleased that we have closed this financing round with such an experienced international venture capital investor like Aescap. Aescap not only puts money on the table, but also the essential expertise to help us build and grow to-BBB into a large biomedical company.” to-BBB is a spin-off from Leiden University. Patrick Krol, partner at Aescap Venture, will chair to-BBB’s Supervisory Board.
Contacts: Aescap Venture Management BV to-BBB technologies BV Patrick Krol Pieter Gaillard Strawinskylaan 629 Einsteinweg 55 World Trade Center B-Toren 2333 CC Amsterdam Leiden
T: +31(0)20 570 2940 T: +31(0)71 527 6268 F: +31(0)20 673 7846 F: +31(0)84 870 9728 E-mail: pkrol@aescap.com E-mail: gaillard@toBBB.com www.aescap.com www.toBBB.com
